- Home
- Publications
- Publication Search
- Publication Details
Title
From Emollients to Biologicals: Targeting Atopic Dermatitis
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 22, Issue 19, Pages 10381
Publisher
MDPI AG
Online
2021-09-27
DOI
10.3390/ijms221910381
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
- (2021) Ashish Bansal et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- JAK inhibitors for atopic dermatitis: a promising treatment modality
- (2021) A.M. Cartron et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- The molecular features of normal and atopic dermatitis skin in infants, children, adolescents and adults
- (2021) Yael Renert-Yuval et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae
- (2021) Magdalena Z. Popiela et al. EYE
- Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect
- (2021) Thanaporn Ratchataswan et al. Journal of Allergy and Clinical Immunology-In Practice
- Biological Therapies for Atopic Dermatitis: A Systematic Review
- (2021) Shuying Zhou et al. DERMATOLOGY
- Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
- (2021) Yael Renert-Yuval et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Atopic Dermatitis
- (2021) Sonja Ständer NEW ENGLAND JOURNAL OF MEDICINE
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
- (2021) Thomas Bieber et al. NEW ENGLAND JOURNAL OF MEDICINE
- The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis
- (2021) Bahareh Hajikhani et al. Antimicrobial Resistance and Infection Control
- Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Kristian Reich et al. LANCET
- OX40L–OX40 Signaling in Atopic Dermatitis
- (2021) Masutaka Furue et al. Journal of Clinical Medicine
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- (2020) E.L. Simpson et al. BRITISH JOURNAL OF DERMATOLOGY
- Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience
- (2020) E Nettis et al. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY
- Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study
- (2020) Hidemi Nakagawa et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effects of Ruxolitinib Cream on Pruritus and Quality of Life in Atopic Dermatitis: Results From a Phase 2, Randomized, Dose-Ranging, Vehicle- and Active-Controlled Study
- (2020) Brian S. Kim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial
- (2020) Joanne R Chalmers et al. LANCET
- Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
- (2020) Emma Guttman-Yassky et al. JAMA Dermatology
- Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
- (2020) Lotte S. Spekhorst et al. ALLERGY
- Delgocitinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Phase 2 Randomized, Double-blind Study of IL-17-Targeting with Secukinumab in Atopic Dermatitis
- (2020) Benjamin Ungar et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis
- (2020) Aaron M. Drucker et al. JAMA Dermatology
- Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: a systematic review for the EAACI Biologicals Guidelines
- (2020) Ioana Agache et al. ALLERGY
- Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
- (2020) Sandra Ferreira et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Drug survival of dupilumab compared to cyclosporin in moderate‐to‐severe atopic dermatitis patients
- (2020) Giacomo Dal Bello et al. Dermatologic Therapy
- Dupilumab for the treatment of adolescents with atopic dermatitis
- (2020) Sonja Senner et al. Expert Review of Clinical Immunology
- Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis
- (2020) H. Nakagawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial
- (2020) Amy S. Paller et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- (2020) Eric L Simpson et al. LANCET
- Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
- (2020) Kenji Kabashima et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic treatments in the management of atopic dermatitis: a systematic review and meta‐analysis
- (2020) Doreen Siegels et al. ALLERGY
- New treatments in atopic dermatitis
- (2020) Neha Puar et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study
- (2020) M.J. Cork et al. BRITISH JOURNAL OF DERMATOLOGY
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
- (2020) A. Wollenberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis
- (2020) Anne-Sofie Halling et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
- (2020) Kristian Reich et al. JAMA Dermatology
- Topical Corticosteroids Normalize both Skin and Systemic Inflammatory Markers in Infant Atopic Dermatitis
- (2020) M.A. McAleer et al. BRITISH JOURNAL OF DERMATOLOGY
- Atopic dermatitis endotypes and implications for targeted therapeutics
- (2019) Tali Czarnowicki et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The oral Janus kinase/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study
- (2019) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Conjunctivitis in dupilumab clinical trials
- (2019) B. Akinlade et al. BRITISH JOURNAL OF DERMATOLOGY
- Genetics of Atopic Dermatitis: From DNA Sequence to Clinical Relevance
- (2019) Mari Løset et al. DERMATOLOGY
- Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis
- (2019) Lorenzo Cosmi et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis
- (2019) Ana B. Pavel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study
- (2019) Mette Deleuran et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis
- (2019) Hidemi Nakagawa et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
- (2019) Robert Bissonnette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
- (2019) Jonathan I. Silverberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream
- (2019) Brian S. Kim et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Evolution of pathologic T-cell subsets in atopic dermatitis from infancy to adulthood
- (2019) Tali Czarnowicki et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Clinical practice guidelines for the management of atopic dermatitis 2018
- (2019) Norito Katoh et al. JOURNAL OF DERMATOLOGY
- Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis
- (2019) Yi-Ling Chen et al. Science Translational Medicine
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
- (2019) Eric L. Simpson et al. JAMA Dermatology
- The role of filaggrin in atopic dermatitis and allergic disease
- (2019) Catherine Drislane et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines
- (2019) Yael Renert-Yuval et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Leveraging the nice face of Janus kinase inhibition—ruxolitinib cream in atopic dermatitis
- (2019) Thomas Bieber JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
- (2019) Hidemi Nakagawa et al. JOURNAL OF DERMATOLOGY
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- (2019) Farzan Solimani et al. Frontiers in Immunology
- Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape
- (2018) Mark Boguniewicz et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- The widespread use of topical antimicrobials enriches for resistance in Staphylococcus aureus isolated from Atopic Dermatitis patients
- (2018) C P Harkins et al. BRITISH JOURNAL OF DERMATOLOGY
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
- (2018) M. de Bruin-Weller et al. BRITISH JOURNAL OF DERMATOLOGY
- Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study
- (2018) Kenji Kabashima et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
- (2018) Andreas Wollenberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis
- (2018) Emma Guttman-Yassky et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis
- (2018) Nick Vandeghinste et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab: A review of its use in the treatment of atopic dermatitis
- (2018) Melinda J. Gooderham et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- An assessment of the use of antihistamines in the management of atopic dermatitis
- (2018) Alice He et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II
- (2018) A. Wollenberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
- (2018) A. Wollenberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- The human skin microbiome
- (2018) Allyson L. Byrd et al. NATURE REVIEWS MICROBIOLOGY
- Significance of Skin Barrier Dysfunction in Atopic Dermatitis
- (2018) Byung Eui Kim et al. Allergy Asthma & Immunology Research
- Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes
- (2018) Ilkka S. Junttila Frontiers in Immunology
- Atopic dermatitis
- (2018) Stephan Weidinger et al. Nature Reviews Disease Primers
- Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab
- (2018) Patrick M. Brunner et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets
- (2018) Elden Berla Thangam et al. Frontiers in Immunology
- The role of the skin microbiome in atopic dermatitis
- (2018) Teruaki Nakatsuji et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis
- (2018) Thomas Werfel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial
- (2018) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics
- (2018) Yik Weng Yew et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
- (2017) Patrick M. Brunner et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Therapeutic pipeline for atopic dermatitis: End of the drought?
- (2017) Amy S. Paller et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council
- (2017) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis
- (2017) Lawrence F. Eichenfield et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
- (2017) Thomas Ruzicka et al. NEW ENGLAND JOURNAL OF MEDICINE
- Staphylococcus aureus and Staphylococcus epidermidis strain diversity underlying pediatric atopic dermatitis
- (2017) Allyson L. Byrd et al. Science Translational Medicine
- Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis
- (2017) Teruaki Nakatsuji et al. Science Translational Medicine
- Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis
- (2016) Elaine C. Siegfried et al. BMC Pediatrics
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development
- (2016) Hitokazu Esaki et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
- (2016) Thomas Werfel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience
- (2016) Joris A. Broeders et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
- (2016) Amy S. Paller et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Atopic dermatitis
- (2016) Stephan Weidinger et al. LANCET
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome of treatment with azathioprine in severe atopic dermatitis: a 5-year retrospective study of adult outpatients
- (2015) S.F. Thomsen et al. BRITISH JOURNAL OF DERMATOLOGY
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
- (2014) Jennifer D. Hamilton et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
- (2014) Eric L. Simpson et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Guidelines of care for the management of atopic dermatitis
- (2014) Lawrence F. Eichenfield et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The Role of Histamine H1 and H4 Receptors in Atopic Dermatitis: From Basic Research to Clinical Study
- (2014) Yusuke Ohsawa et al. ALLERGOLOGY INTERNATIONAL
- A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
- (2013) Maryam Salimi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nonpathogenic Bacteria Alleviating Atopic Dermatitis Inflammation Induce IL-10-Producing Dendritic Cells and Regulatory Tr1 Cells
- (2013) Thomas Volz et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
- (2012) Julia K. Gittler et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Pruritus and Atopic Dermatitis
- (2011) Ulf Darsow et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- A randomized trial of methotrexate versus azathioprine for severe atopic eczema
- (2011) Mandy Elvira Schram et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: A randomized controlled trial
- (2011) Inge M. Haeck et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Filaggrin Mutations Associated with Skin and Allergic Diseases
- (2011) Alan D. Irvine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials
- (2010) J. Schmitt et al. BRITISH JOURNAL OF DERMATOLOGY
- Epidermal Barrier Dysfunction in Atopic Dermatitis
- (2009) Michael J. Cork et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment
- (2008) A. Wollenberg et al. ALLERGY
- Effects of nonpathogenic gram-negative bacteriumVitreoscilla filiformislysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study
- (2008) A. Gueniche et al. BRITISH JOURNAL OF DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started